MicroRNA-135b Promotes Cancer Progression by Acting As a Downstream Effector of Oncogenic Pathways in Colon Cancer

Overview

Journal Cancer Cell

Publisher Cell Press

Specialty Oncology

Date 2014 Apr 17

PMID 24735923

Citations 183

Authors

Nicola Valeri

Chiara Braconi

Pierluigi Gasparini

Claudio Murgia

Andrea Lampis

Viola Paulus-Hock

Jonathan R Hart

Lynn Ueno

Sergei I Grivennikov

Francesca Lovat

Alessio Paone

Luciano Cascione

Khlea M Sumani

Angelo Veronese

Muller Fabbri

Stefania Carasi

Hansjuerg Alder

Giovanni Lanza

Roberta Gafa

Mary P Moyer

Rachel A Ridgway

Julia Cordero

Gerard J Nuovo

Wendy L Frankel

Massimo Rugge

Matteo Fassan

Joanna Groden

Peter K Vogt

Michael Karin

Owen J Sansom

Carlo M Croce

Affiliations

Soon will be listed here.

Abstract

MicroRNA deregulation is frequent in human colorectal cancers (CRCs), but little is known as to whether it represents a bystander event or actually drives tumor progression in vivo. We show that miR-135b overexpression is triggered in mice and humans by APC loss, PTEN/PI3K pathway deregulation, and SRC overexpression and promotes tumor transformation and progression. We show that miR-135b upregulation is common in sporadic and inflammatory bowel disease-associated human CRCs and correlates with tumor stage and poor clinical outcome. Inhibition of miR-135b in CRC mouse models reduces tumor growth by controlling genes involved in proliferation, invasion, and apoptosis. We identify miR-135b as a key downsteam effector of oncogenic pathways and a potential target for CRC treatment.

Citing Articles

Advances in microRNAs as Emerging Biomarkers for Colorectal Cancer Early Detection and Diagnosis.

Zdralevic M, Radovic A, Raonic J, Popovic N, Klisic A, Vuckovic L Int J Mol Sci. 2024; 25(20).

PMID: 39456841 PMC: 11507567. DOI: 10.3390/ijms252011060.

Three-layer heterogeneous network based on the integration of CircRNA information for MiRNA-disease association prediction.

Qu J, Liu S, Li H, Zhou J, Bian Z, Song Z PeerJ Comput Sci. 2024; 10:e2070.

PMID: 38983241 PMC: 11232581. DOI: 10.7717/peerj-cs.2070.

Bcl-2 Up-Regulation Mediates Taxane Resistance Downstream of APC Loss.

Wise A, Maloney S, Hering A, Zabala S, Richmond G, VanKlompenberg M Int J Mol Sci. 2024; 25(12).

PMID: 38928449 PMC: 11203545. DOI: 10.3390/ijms25126745.

Hypoxia‑regulated exosomal miR‑185 inhibits esophageal squamous cell carcinoma progression and predicts prognosis.

Maiyulan A, Matsumoto Y, Wang H, Murakami K, Toyozumi T, Otsuka R Oncol Lett. 2024; 28(1):334.

PMID: 38827568 PMC: 11140231. DOI: 10.3892/ol.2024.14467.

Analysis of the differential expression of serum miR-21-5p, miR-135-5p, and miR-155-5p by Bifidobacterium triplex viable capsules during the perioperative stage of colorectal cancer.

Zhang J, Guo J, He R, Li J, Du B, Zhang Y Int J Colorectal Dis. 2024; 39(1):48.

PMID: 38584226 PMC: 10999390. DOI: 10.1007/s00384-024-04617-8.

References

Sansom O, Reed K, van de Wetering M, Muncan V, Winton D, Clevers H . Cyclin D1 is not an immediate target of beta-catenin following Apc loss in the intestine. J Biol Chem. 2005; 280(31):28463-7. DOI: 10.1074/jbc.M500191200. View

Guda K, Giardina C, Nambiar P, Cui H, Rosenberg D . Aberrant transforming growth factor-beta signaling in azoxymethane-induced mouse colon tumors. Mol Carcinog. 2001; 31(4):204-13. DOI: 10.1002/mc.1055. View

Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D . Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012; 483(7387):100-3. DOI: 10.1038/nature10868. View

Sjoblom T, Jones S, Wood L, Parsons D, Lin J, Barber T . The consensus coding sequences of human breast and colorectal cancers. Science. 2006; 314(5797):268-74. DOI: 10.1126/science.1133427. View

Serrels A, Macpherson I, Evans T, Lee F, Clark E, Sansom O . Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther. 2006; 5(12):3014-22. DOI: 10.1158/1535-7163.MCT-06-0382. View

Groden J, Joslyn G, Samowitz W, Jones D, Bhattacharyya N, Spirio L . Response of colon cancer cell lines to the introduction of APC, a colon-specific tumor suppressor gene. Cancer Res. 1995; 55(7):1531-9. View

Valeri N, Croce C, Fabbri M . Pathogenetic and clinical relevance of microRNAs in colorectal cancer. Cancer Genomics Proteomics. 2009; 6(4):195-204. View

Hart J, Liao L, Ueno L, Yates 3rd J, Vogt P . Protein expression profiles of C3H 10T1/2 murine fibroblasts and of isogenic cells transformed by the H1047R mutant of phosphoinositide 3-kinase (PI3K). Cell Cycle. 2011; 10(6):971-6. PMC: 3100876. DOI: 10.4161/cc.10.6.15077. View

Hinoi T, Akyol A, Theisen B, Ferguson D, Greenson J, Williams B . Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res. 2007; 67(20):9721-30. DOI: 10.1158/0008-5472.CAN-07-2735. View

10.

Chen J, Huang X . The signal pathways in azoxymethane-induced colon cancer and preventive implications. Cancer Biol Ther. 2009; 8(14):1313-7. DOI: 10.4161/cbt.8.14.8983. View

11.

Qian J, Sarnaik A, Bonney T, Keirsey J, Combs K, Steigerwald K . The APC tumor suppressor inhibits DNA replication by directly binding to DNA via its carboxyl terminus. Gastroenterology. 2008; 135(1):152-62. PMC: 2832605. DOI: 10.1053/j.gastro.2008.03.074. View

12.

Matsuyama H, Suzuki H, Nishimori H, Noguchi M, Yao T, Komatsu N . miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. Blood. 2011; 118(26):6881-92. DOI: 10.1182/blood-2011-05-354654. View

13.

Marsh V, Winton D, Williams G, Dubois N, Trumpp A, Sansom O . Epithelial Pten is dispensable for intestinal homeostasis but suppresses adenoma development and progression after Apc mutation. Nat Genet. 2008; 40(12):1436-44. DOI: 10.1038/ng.256. View

14.

Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R . Fast and effective prediction of microRNA/target duplexes. RNA. 2004; 10(10):1507-17. PMC: 1370637. DOI: 10.1261/rna.5248604. View

15.

Borinstein S, Conerly M, Dzieciatkowski S, Biswas S, Washington M, Trobridge P . Aberrant DNA methylation occurs in colon neoplasms arising in the azoxymethane colon cancer model. Mol Carcinog. 2009; 49(1):94-103. PMC: 2875385. DOI: 10.1002/mc.20581. View

16.

Catenacci D, Kozloff M, Kindler H, Polite B . Personalized colon cancer care in 2010. Semin Oncol. 2011; 38(2):284-308. PMC: 3065981. DOI: 10.1053/j.seminoncol.2011.01.001. View

17.

Rojas A, Padidam M, Cress D, Grady W . TGF-beta receptor levels regulate the specificity of signaling pathway activation and biological effects of TGF-beta. Biochim Biophys Acta. 2009; 1793(7):1165-73. PMC: 2700179. DOI: 10.1016/j.bbamcr.2009.02.001. View

18.

Ghafouri-Fard S, Ousati Ashtiani Z, Sabah Golian B, Hasheminasab S, Modarressi M . Expression of two testis-specific genes, SPATA19 and LEMD1, in prostate cancer. Arch Med Res. 2010; 41(3):195-200. DOI: 10.1016/j.arcmed.2010.04.003. View

19.

Mukherji S, Ebert M, Zheng G, Tsang J, Sharp P, van Oudenaarden A . MicroRNAs can generate thresholds in target gene expression. Nat Genet. 2011; 43(9):854-9. PMC: 3163764. DOI: 10.1038/ng.905. View

20.

Mahon P, Hirota K, Semenza G . FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001; 15(20):2675-86. PMC: 312814. DOI: 10.1101/gad.924501. View